Medicine and Dentistry
Combination Therapy
100%
Nodular Melanoma
100%
Serum
50%
Biological Marker
50%
Monotherapy
50%
Tumor Progression
50%
Nivolumab
50%
Trametinib
50%
Dabrafenib
50%
Diseases
25%
Neoplasm
25%
Disease Exacerbation
25%
Macrophage
25%
Development
25%
Drug
25%
MEK Inhibitor
25%
Chemotherapeutic Agent
25%
Introspection
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Tumor Growth
50%
Biological Marker
50%
Monotherapy
50%
Nivolumab
50%
Trametinib
50%
Immune Checkpoint Inhibitor
50%
Dabrafenib
50%
Diseases
25%
Disease Exacerbation
25%
Neoplasm
25%
Mitogen Activated Protein Kinase Kinase Inhibitor
25%
Drug
25%
Biochemistry, Genetics and Molecular Biology
Tumor Progression
50%
CXCL10
50%
Trametinib
50%
Dabrafenib
50%
CCL22
50%
Blood Level
25%
Development
25%
Mitogen-Activated Protein Kinase Kinase
25%
Tumor-Associated Macrophage
25%
Time
25%
Introspection
25%
Immunology and Microbiology
CXCL10
50%
Nivolumab
50%
CCL22
50%
Trametinib
50%
Blood Level
25%
Tumor-Associated Macrophage
25%
Development
25%
Time
25%
Introspection
25%
Immunity
25%
Neuroscience
CXCL10
50%
Trametinib
50%
Dabrafenib
50%
Nivolumab
50%
CCL22
50%
Mitogen-Activated Protein Kinase Kinase
25%